Rezolute, Inc. RZLT
We take great care to ensure that the data presented and summarized in this overview for Rezolute, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RZLT
View all-
Federated Hermes, Inc. Pittsburgh, PA11.3MShares$46 Million0.13% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.8MShares$11.4 Million1.99% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.58MShares$10.5 Million0.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.93MShares$7.88 Million0.0% of portfolio
-
Blackstone Inc New York, NY1.74MShares$7.12 Million0.04% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.7MShares$6.94 Million1.42% of portfolio
-
Altium Capital Management LP New York, NY1.7MShares$6.94 Million2.91% of portfolio
-
Adar1 Capital Management, LLC Austin, TX1.57MShares$6.41 Million1.24% of portfolio
-
Ghost Tree Capital, LLC New York, NY1.47MShares$6.02 Million2.68% of portfolio
-
Caxton Corp Princeton, NJ1.32MShares$5.38 Million27.47% of portfolio
Latest Institutional Activity in RZLT
Top Purchases
Top Sells
About RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Insider Transactions at RZLT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2025
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
10,549
+7.41%
|
$52,745
$5.04 P/Share
|
|
Dec 18
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
10,000
+6.22%
|
$40,000
$4.29 P/Share
|
|
Dec 12
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
9,000
+6.0%
|
$36,000
$4.6 P/Share
|
|
Sep 24
2024
|
Wladimir Hogenhuis |
BUY
Open market or private purchase
|
Direct |
4,259
+9.25%
|
$17,036
$4.7 P/Share
|
|
Jun 25
2024
|
Wladimir Hogenhuis |
BUY
Open market or private purchase
|
Direct |
4,815
+11.38%
|
$19,260
$4.15 P/Share
|
|
Jun 14
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Indirect |
3,300
+18.32%
|
$9,900
$3.94 P/Share
|
|
Jun 14
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
4,300
+3.72%
|
$12,900
$3.94 P/Share
|
|
Jun 14
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Indirect |
40,000
+50.0%
|
$160,000
$4.04 P/Share
|
|
May 29
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
451
+0.37%
|
$1,353
$3.5 P/Share
|
|
May 24
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Indirect |
2,942
+18.45%
|
$8,826
$3.23 P/Share
|
|
May 23
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
7,500
+7.0%
|
$15,000
$2.7 P/Share
|
|
May 23
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Indirect |
58
+0.57%
|
$116
$2.85 P/Share
|
|
Mar 28
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Indirect |
500
+31.73%
|
$1,000
$2.55 P/Share
|
|
Mar 15
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Indirect |
20,000
+50.0%
|
$20,000
$1.69 P/Share
|
|
Mar 14
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$10,000
$1.88 P/Share
|
|
Mar 08
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
50,000
+29.26%
|
$50,000
$1.93 P/Share
|
|
Mar 07
2024
|
Young Jin Kim |
BUY
Open market or private purchase
|
Direct |
36,503
+24.02%
|
$36,503
$1.91 P/Share
|
|
Mar 07
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Indirect |
500
+50.0%
|
$500
$1.85 P/Share
|
|
Feb 26
2024
|
Nevan C Elam CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+39.01%
|
$5,000
$1.68 P/Share
|
|
Feb 26
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+4.49%
|
$2,000
$1.7 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 286K shares |
|---|